menu search

Lexeo therapeutics announces pricing of initial public offering

NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) — Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to transform...

November 3, 2023, 1:51 am

Cassava sciences: my bullish take on biomarkers and ctad data

Cassava Sciences' stock is highly disputed due to conflicting opinions on the science behind its drug candidate, but outside research supports its app...

October 30, 2023, 3:30 am

alzheimer's medication: eisai reporting positive data on injectable drug

This segment originally aired on October 26, 2023. Eisai has (EISAY) reported positive results in clinical trials of their ...

October 28, 2023, 9:00 am

Acumen pharmaceuticals presents late-breaker phase 1 updates exploring novel target engagement, dosing regimen and safety findings for acu193 in early alzheimer’s disease at the 16th annual clinical t

– Acumen presented data exploring target engagement modeling of ACU193, the first clinical-stage amyloid beta oligomer (AβO)-targeting antibody, to...

October 27, 2023, 1:25 pm

Cognition therapeutics and collaborators at yale and actc announce oral late-breaking presentation on the start study in early alzheimer’s disease at ctad

NEW YORK, Oct. 27, 2023 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced that Christoper van Dyck, M.D., the director of the...

October 27, 2023, 11:30 am

Seelos therapeutics to present a poster on sls-005 in alzheimer's disease at neuroscience 2023

-SLS-005 induces autophagy to reduce mutant protein aggregates, and is currently being studied in alzheimer...

October 27, 2023, 8:11 am

Biogen and eisai's revised alzheimer's drug works, but safety questions linger

Wall Street analysts say Biogen and Eisai could secure Food and Drug Administration approval for their injected ...

October 26, 2023, 10:35 am

: biogen and eisai release new alzheimer’s drug data that may support wider uptake

Eisai plans to apply for FDA approval of subcutaneous Leqembi by early next year. Read Full Story The post : Biogen and Eisai release new ...

October 25, 2023, 9:28 pm

Eisai presents new leqembi® (lecanemab-irmb) investigational subcutaneous formulation interim study results and clinical improvement data in earlier stages of early alzheimer’s disease from additional

Investigational Subcutaneous Formulation Clears 14% More Plaque Than IV, Pharmacokinetics (AUC) 11% Higher, And Similar ARIA Rates To IV 76% Of Patien...

October 25, 2023, 9:26 pm

Eisai presents new leqembi® (lecanemab-irmb) investigational subcutaneous formulation interim study results and clinical improvement data in earlier stages of early alzheimer’s disease from additional

Investigational Subcutaneous Formulation Clears 14% More Plaque Than IV, Pharmacokinetics (AUC) 11% Higher, And Similar ARIA Rates To IV 76% Of Patien...

October 25, 2023, 9:26 pm

Biogen and eisai release new alzheimer's drug data that may support wider uptake

Biogen Inc. and Eisai Co. late Wednesday released new data on their alzheimer's treatment Leqembi that ...

October 25, 2023, 5:28 pm

New data from biogen’s investigational antisense oligonucleotide (aso) targeting tau shows promise for potential new generation of treatments in early alzheimer’s disease

In the Phase 1b study, favorable trends were reported for the high-dose groups on multiple measures of cognition and function. First study of a tau ta...

October 25, 2023, 2:51 pm

Biovie says blinded data points to hopeful alzheimer's treatment potential

BioVie Inc (NASDAQ:BIVI) said that blinded data presented at the 16th Clinical Trials on alzheimer's Di...

October 25, 2023, 2:19 pm

Bioxcel therapeutics shares pop after audit of alzheimer's trial data

Shares of BioXcel Therapeutics Inc. BTAI, +0.86% jumped more than 40% premarket on Wednesday after the company said an independent audit of ...

October 25, 2023, 8:44 am

Allyx therapeutics to present phase 1 data for lead compound alx-001 at the 16th clinical trials on alzheimer’s disease meeting

Allyx’s lead compound, ALX-001, is a small molecule with unique mechanism of action at mGluR5, to protect and preserve synapses in neurodegenerative...

October 19, 2023, 8:05 pm

Biogen to present new data at the clinical trials on alzheimer's disease (ctad) 2023 meeting

CAMBRIDGE, Mass., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) will present new data from its ...

October 19, 2023, 7:30 am

Prothena shares buoyed by sale rumors

Shares of Prothena Corporation (NASDAQ:PRTA) added almost 25% on rumours the biotechnology firm is exploring a sale ahead of the release of key data f...

October 16, 2023, 12:09 pm

Longeveron announces closing of $4 million registered direct offering priced at-the-market under nasdaq rules

MIAMI, Oct. 13, 2023 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company d...

October 13, 2023, 8:05 pm

Annovis (anvs) ad study to continue as planned, shares rise

Annovis (ANVS) gains on the release of interim independent analysis, indicating that the ongoing phase II/III study in ...

October 13, 2023, 2:16 pm

Cassava sciences slumps after leaked report claims 'egregious misconduct' over alzheimer's drug

Cassava Sciences Inc has denied data manipulation after a probe into conduct over its alzheimer's drug ...

October 13, 2023, 10:06 am


Search within

Pages Search Results: